{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T02:28:25Z","timestamp":1786588105158,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50196516"],"award-info":[{"award-number":["P50196516"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["HT9425-24-1-0702"],"award-info":[{"award-number":["HT9425-24-1-0702"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["HT9425-24-1-0703"],"award-info":[{"award-number":["HT9425-24-1-0703"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>PARP inhibitors have demonstrated notable clinical benefit, particularly in tumors with BRCA1\/2 mutations. Clear cell renal cell carcinoma (ccRCC) carrying wild type (WT) BRCA1\/2 is resistant to PARP inhibitor monotherapy. Strategies to enhance the sensitivity of BRCA1\/2-WT ccRCC to PARP inhibitors remain challenging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An in vitro chemical screen was performed to identify alkylating agents that synergize with PARP inhibition using cell viability assays. ccRCC sensitivity to individual alkylating agents was further assessed by measuring PARP-1 activity. The therapeutic effects of monotherapy and combination treatment with alkylating agents and PARP inhibitors were evaluated through DNA damage repair assays, cell viability assays, colony formation assays, ccRCC cell xenograft assays, and ccRCC patient-derived xenograft assays. Mechanistic insights and DNA repair pathway involvement were assessed using comparative expression profiling and gain- and loss-of-function approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>BRCA1\/2-WT ccRCC exhibits markedly higher PARP-1 activity compared to breast cancers. A subset of alkylating agents, including Temozolomide (TMZ) and Streptozocin, is identified to induce hyperactivation of PARP-1, creating a PARP-1 dependency in ccRCC cells that renders these cells sensitive to PARP inhibitors in vitro and in mice. Mechanistically, SLFN11 is selectively upregulated and boosts proteasomal degradation of BRCA1 protein in ccRCC cells. Loss of SLFN11 increases BRCA1 levels and enhances homologous recombination repair, mitigating prolonged excessive DNA damage in ccRCC cells following combination treatment with TMZ and Olaparib. SLFN11 is inversely correlated with BRCA1 expression and potentiates the therapeutic efficacy of TMZ and Olaparib combination treatment in ccRCC patient-derived xenograft models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings reveal an intrinsic SLFN11-dependent vulnerability in ccRCC that synergizes with alkylating agents to induce an acquired PARP-1 dependency, thereby sensitizing BRCA1\/2-WT tumors to PARP inhibition. Therefore, this work uncovers a potential therapeutic strategy for targeting SLFN11-high kidney cancers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03743-1","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:15:29Z","timestamp":1780964129000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Alkylating agents activate an SLFN11-dependent vulnerability that confers PARP-1 inhibitor sensitivity in kidney cancer"],"prefix":"10.1186","volume":"45","author":[{"given":"Chenliang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanina","family":"Toffessi Tcheuyap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Brugarolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibo","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"3743_CR1","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1086\/279847","volume":"56","author":"CB Bridges","year":"1922","unstructured":"Bridges CB. The origin of variations in sexual and sex-limited characters. Am Nat. 1922;56:642.","journal-title":"Am Nat"},{"issue":"7035","key":"3743_CR2","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913\u20137.","journal-title":"Nature"},{"issue":"7035","key":"3743_CR3","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917\u201321.","journal-title":"Nature"},{"issue":"1","key":"3743_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","volume":"18","author":"EM Swisher","year":"2017","unstructured":"Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75\u201387.","journal-title":"Lancet Oncol"},{"issue":"15","key":"3743_CR5","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"J Ledermann","year":"2012","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382\u201392.","journal-title":"N Engl J Med"},{"issue":"6330","key":"3743_CR6","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science. 2017;355(6330):1152\u20138.","journal-title":"Science"},{"issue":"7","key":"3743_CR7","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1158\/2159-8290.CD-20-1503","volume":"11","author":"J Setton","year":"2021","unstructured":"Setton J, Zinda M, Riaz N, Durocher D, Zimmermann M, Koehler M, et al. Synthetic Lethality in Cancer Therapeutics: The Next Generation. Cancer Discov. 2021;11(7):1626\u201335.","journal-title":"Cancer Discov"},{"issue":"9","key":"3743_CR8","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/s41571-018-0055-6","volume":"15","author":"A Ashworth","year":"2018","unstructured":"Ashworth A, Lord CJ. Synthetic lethal therapies for cancer: what\u2019s next after PARP inhibitors? Nat Rev Clin Oncol. 2018;15(9):564\u201376.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"3743_CR9","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1158\/0008-5472.CAN-23-0628","volume":"83","author":"J Murai","year":"2023","unstructured":"Murai J, Pommier Y, BRCAness. Homologous Recombination Deficiencies, and Synthetic Lethality. Cancer Res. 2023;83(8):1173\u20134.","journal-title":"Cancer Res"},{"key":"3743_CR10","doi-asserted-by":"crossref","unstructured":"Guo M, Wang SM. The BRCAness Landscape of Cancer. Cells. 2022;11(23):3877.","DOI":"10.3390\/cells11233877"},{"issue":"8","key":"3743_CR11","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-020-0301-x","volume":"16","author":"N Dizman","year":"2020","unstructured":"Dizman N, Philip EJ, Pal SK. Genomic profiling in renal cell carcinoma. Nat Rev Nephrol. 2020;16(8):435\u201351.","journal-title":"Nat Rev Nephrol"},{"issue":"22","key":"3743_CR12","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1158\/0008-5472.CAN-23-0401","volume":"83","author":"X Zhou","year":"2023","unstructured":"Zhou X, Sekino Y, Li HT, Fu G, Yang Z, Zhao S, et al. SETD2 Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in Kidney Cancer. Cancer Res. 2023;83(22):3813\u201326.","journal-title":"Cancer Res"},{"key":"3743_CR13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/978-3-031-30065-3_10","volume":"186","author":"EK Lee","year":"2023","unstructured":"Lee EK, Liu JF. Rational Combinations of PARP Inhibitors with HRD-Inducing Molecularly Targeted Agents. Cancer Treat Res. 2023;186:171\u201388.","journal-title":"Cancer Treat Res"},{"issue":"2","key":"3743_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nrc3185","volume":"12","author":"D Fu","year":"2012","unstructured":"Fu D, Calvo JA, Samson LD. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer. 2012;12(2):104\u201320.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"3743_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/ctrv.2000.0170","volume":"26","author":"MJ Maanen","year":"2000","unstructured":"Maanen MJ, Smeets CJ, Beijnen JH. Chemistry, pharmacology and pharmacokinetics of N,N\u2019,N -triethylenethiophosphoramide (ThioTEPA). Cancer Treat Rev. 2000;26(4):257\u201368.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"3743_CR16","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1042\/bj1160693","volume":"116","author":"PD Lawley","year":"1970","unstructured":"Lawley PD, Thatcher CJ. Methylation of deoxyribonucleic acid in cultured mammalian cells by N-methyl-N\u2019-nitro-N-nitrosoguanidine. The influence of cellular thiol concentrations on the extent of methylation and the 6-oxygen atom of guanine as a site of methylation. Biochem J. 1970;116(4):693\u2013707.","journal-title":"Biochem J"},{"issue":"11","key":"3743_CR17","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.dnarep.2004.05.004","volume":"3","author":"F Drablos","year":"2004","unstructured":"Drablos F, Feyzi E, Aas PA, Vaagbo CB, Kavli B, Bratlie MS, et al. Alkylation damage in DNA and RNA\u2013repair mechanisms and medical significance. DNA Repair (Amst). 2004;3(11):1389\u2013407.","journal-title":"DNA Repair (Amst)"},{"issue":"11","key":"3743_CR18","doi-asserted-by":"publisher","first-page":"6313","DOI":"10.1093\/nar\/gkac471","volume":"50","author":"M Yang","year":"2022","unstructured":"Yang M, Wang C, Zhou M, Bao L, Wang Y, Kumar A, et al. KDM6B promotes PARthanatos via suppression of O6-methylguanine DNA methyltransferase repair and sustained checkpoint response. Nucleic Acids Res. 2022;50(11):6313\u201331.","journal-title":"Nucleic Acids Res"},{"key":"3743_CR19","doi-asserted-by":"publisher","first-page":"101092","DOI":"10.1016\/j.neo.2024.101092","volume":"59","author":"R Caggiano","year":"2025","unstructured":"Caggiano R, Prokhorova E, Duma L, Schutzenhofer K, Lauro R, Catara G, et al. Suppression of ADP-ribosylation reversal triggers cell vulnerability to alkylating agents. Neoplasia. 2025;59:101092.","journal-title":"Neoplasia"},{"key":"3743_CR20","doi-asserted-by":"publisher","first-page":"102651","DOI":"10.1016\/j.dnarep.2019.102651","volume":"81","author":"Y Wang","year":"2019","unstructured":"Wang Y, Luo W, Wang Y. PARP-1 and its associated nucleases in DNA damage response. DNA Repair (Amst). 2019;81:102651.","journal-title":"DNA Repair (Amst)"},{"issue":"10","key":"3743_CR21","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrm.2017.53","volume":"18","author":"A Ray Chaudhuri","year":"2017","unstructured":"Ray Chaudhuri A, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 2017;18(10):610\u201321.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"3743_CR22","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1101\/gad.183509.111","volume":"26","author":"X Luo","year":"2012","unstructured":"Luo X, Kraus WL. On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev. 2012;26(5):417\u201332.","journal-title":"Genes Dev"},{"issue":"6","key":"3743_CR23","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.molcel.2015.01.034","volume":"58","author":"P Bai","year":"2015","unstructured":"Bai P. Biology of Poly(ADP-Ribose) Polymerases: The Factotums of Cell Maintenance. Mol Cell. 2015;58(6):947\u201358.","journal-title":"Mol Cell"},{"issue":"1","key":"3743_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.yexcr.2014.07.003","volume":"329","author":"C Beck","year":"2014","unstructured":"Beck C, Robert I, Reina-San-Martin B, Schreiber V, Dantzer F. Poly(ADP-ribose) polymerases in double-strand break repair: focus on PARP1, PARP2 and PARP3. Exp Cell Res. 2014;329(1):18\u201325.","journal-title":"Exp Cell Res"},{"issue":"47","key":"3743_CR25","doi-asserted-by":"publisher","first-page":"76534","DOI":"10.18632\/oncotarget.12266","volume":"7","author":"J Murai","year":"2016","unstructured":"Murai J, Feng Y, Yu GK, Ru Y, Tang SW, Shen Y, et al. Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Oncotarget. 2016;7(47):76534\u201350.","journal-title":"Oncotarget"},{"issue":"2","key":"3743_CR26","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1158\/1078-0432.CCR-16-1040","volume":"23","author":"BH Lok","year":"2017","unstructured":"Lok BH, Gardner EE, Schneeberger VE, Ni A, Desmeules P, Rekhtman N, et al. PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. Clin Cancer Res. 2017;23(2):523\u201335.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"3743_CR27","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1200\/JCO.2018.77.7672","volume":"36","author":"MC Pietanza","year":"2018","unstructured":"Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, et al. Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J Clin Oncol. 2018;36(23):2386\u201394.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3743_CR28","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1182\/blood.2019003782","volume":"137","author":"Y Okamoto","year":"2021","unstructured":"Okamoto Y, Abe M, Mu A, Tempaku Y, Rogers CB, Mochizuki AL, et al. SLFN11 promotes stalled fork degradation that underlies the phenotype in Fanconi anemia cells. Blood. 2021;137(3):336\u201348.","journal-title":"Blood"},{"issue":"11","key":"3743_CR29","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/s41594-018-0142-5","volume":"25","author":"M Li","year":"2018","unstructured":"Li M, Kao E, Malone D, Gao X, Wang JYJ, David M. DNA damage-induced cell death relies on SLFN11-dependent cleavage of distinct type II tRNAs. Nat Struct Mol Biol. 2018;25(11):1047\u201358.","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"3743_CR30","doi-asserted-by":"publisher","first-page":"94","DOI":"10.15252\/embr.201540964","volume":"17","author":"Y Mu","year":"2016","unstructured":"Mu Y, Lou J, Srivastava M, Zhao B, Feng XH, Liu T, et al. SLFN11 inhibits checkpoint maintenance and homologous recombination repair. EMBO Rep. 2016;17(1):94\u2013109.","journal-title":"EMBO Rep"},{"issue":"5","key":"3743_CR31","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1172\/JCI95089","volume":"128","author":"Y Chen","year":"2018","unstructured":"Chen Y, Zhang B, Bao L, Jin L, Yang M, Peng Y, et al. ZMYND8 acetylation mediates HIF-dependent breast cancer progression and metastasis. J Clin Invest. 2018;128(5):1937\u201355.","journal-title":"J Clin Invest"},{"key":"3743_CR32","doi-asserted-by":"crossref","unstructured":"Wang Y, An R, Umanah GK, Park H, Nambiar K, Eacker SM et al. A nuclease that mediates cell death induced by DNA damage and poly(ADP-ribose) polymerase-1. Science. 2016;354(6308):aad6872.","DOI":"10.1126\/science.aad6872"},{"issue":"8","key":"3743_CR33","doi-asserted-by":"publisher","first-page":"110055","DOI":"10.1016\/j.celrep.2021.110055","volume":"37","author":"R Elias","year":"2021","unstructured":"Elias R, Tcheuyap VT, Kaushik AK, Singla N, Gao M, Reig Torras O, et al. A renal cell carcinoma tumorgraft platform to advance precision medicine. Cell Rep. 2021;37(8):110055.","journal-title":"Cell Rep"},{"issue":"28","key":"3743_CR34","doi-asserted-by":"publisher","first-page":"11832","DOI":"10.1073\/pnas.0702176104","volume":"104","author":"EA Bey","year":"2007","unstructured":"Bey EA, Bentle MS, Reinicke KE, Dong Y, Yang CR, Girard L, et al. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. Proc Natl Acad Sci U S A. 2007;104(28):11832\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"3743_CR35","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1006\/taap.2002.9438","volume":"182","author":"TJ Liu","year":"2002","unstructured":"Liu TJ, Lin SY, Chau YP. Inhibition of poly(ADP-ribose) polymerase activation attenuates beta-lapachone-induced necrotic cell death in human osteosarcoma cells. Toxicol Appl Pharmacol. 2002;182(2):116\u201325.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"4","key":"3743_CR36","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2008.04.009","volume":"30","author":"WG Kaelin Jr","year":"2008","unstructured":"Kaelin WG Jr., Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008;30(4):393\u2013402.","journal-title":"Mol Cell"},{"issue":"15","key":"3743_CR37","doi-asserted-by":"publisher","first-page":"6384","DOI":"10.1158\/0008-5472.CAN-10-1304","volume":"70","author":"W Wu","year":"2010","unstructured":"Wu W, Sato K, Koike A, Nishikawa H, Koizumi H, Venkitaraman AR, et al. HERC2 is an E3 ligase that targets BRCA1 for degradation. Cancer Res. 2010;70(15):6384\u201392.","journal-title":"Cancer Res"},{"issue":"4","key":"3743_CR38","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.bbrc.2014.01.075","volume":"444","author":"X Wang","year":"2014","unstructured":"Wang X, Lu G, Li L, Yi J, Yan K, Wang Y, et al. HUWE1 interacts with BRCA1 and promotes its degradation in the ubiquitin-proteasome pathway. Biochem Biophys Res Commun. 2014;444(4):549\u201354.","journal-title":"Biochem Biophys Res Commun"},{"issue":"49","key":"3743_CR39","doi-asserted-by":"publisher","first-page":"41014","DOI":"10.1074\/jbc.M112.407106","volume":"287","author":"Y Lu","year":"2012","unstructured":"Lu Y, Li J, Cheng D, Parameswaran B, Zhang S, Jiang Z, et al. The F-box protein FBXO44 mediates BRCA1 ubiquitination and degradation. J Biol Chem. 2012;287(49):41014\u201322.","journal-title":"J Biol Chem"},{"key":"3743_CR40","doi-asserted-by":"crossref","unstructured":"Jo U, Murai Y, Chakka S, Chen L, Cheng K, Murai J et al. SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR\/CHK1 inhibitors. Proc Natl Acad Sci U S A. 2021;118(6):e2015654118.","DOI":"10.1073\/pnas.2015654118"},{"issue":"1","key":"3743_CR41","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1158\/1078-0432.CCR-24-2350","volume":"31","author":"CB Meador","year":"2025","unstructured":"Meador CB, Digumarthy SR, Yeap BY, Hung YP, Mino-Kenudson M, Farago AF, et al. Phase I\/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes. Clin Cancer Res. 2025;31(1):25\u201334.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3743_CR42","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00280-013-2113-1","volume":"71","author":"R Plummer","year":"2013","unstructured":"Plummer R, Lorigan P, Steven N, Scott L, Middleton MR, Wilson RH, et al. A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother Pharmacol. 2013;71(5):1191\u20139.","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03743-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03743-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03743-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T02:05:23Z","timestamp":1786586723000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03743-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3743"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03743-1","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animal studies were approved and conducted under the oversight of the UT Southwestern Institutional Animal Care and Use Committee. Human ccRCC PDX tumors were approved by the Institutional Review Board at UT Southwestern Medical Center with written informed consent and generated as described previously [\n                      \n                      ].","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JB reports personal fees from Arrowhead Pharmaceuticals, Calithera, Eisai, Exelixis, Johnson and Johnson, and Telix outside the submitted work. JB has patents\/applications pertaining to HIF2. None of these activities are related or relevant to the work presented herein. Other authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"176"}}